恒生生物科技指数

Search documents
港股,重大调整!
Zheng Quan Shi Bao· 2025-08-22 11:41
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 8月22日,恒生指数有限公司(简称"恒生指数公司")宣布截至2025年6月30日的恒生指数系列季度检讨结 果,其中在港股市场最受关注的指数之一——恒生指数,成份股数目将进一步增加,由85只增加至88只, 加入中国电信、京东物流、泡泡玛特3只股票。 恒生指数成份股又扩容了! 8月22日,根据恒生指数公司发布的新闻稿,港股市场将调整多个指数成份股,其中恒生指数成份股将由85 只进一步增加至88只。 恒生综合指数成份股数目也有所扩容,由502只增加至504只。 上述变动将于2025年9月5日(星期五)收市后实施,并于2025年9月8日(星期一)起生效。 值得注意的是,这是恒生指数成份股的进一步扩容。此前,在恒生指数公司宣布的截至2025年3月31日的恒 生指数系列季度检讨结果中,恒生指数成份股由83只增加至85只。 恒生指数成份股再"扩容" | | | | 代號 | 公司 | 恒指分類指數 | | --- | --- | --- | | 728 | 中國電信股份有限公司 - H 股 | 恒生工商業分類指數 | | 2618 | 京東物流股份有 ...
港股,重大调整
Zheng Quan Shi Bao· 2025-08-22 11:41
8月22日,根据恒生指数公司发布的新闻稿,港股市场将调整多个指数成份股,其中恒生指数成份股将由85 只进一步增加至88只。 恒生综合指数成份股数目也有所扩容,由502只增加至504只。 上述变动将于2025年9月5日(星期五)收市后实施,并于2025年9月8日(星期一)起生效。 值得注意的是,这是恒生指数成份股的进一步扩容。此前,在恒生指数公司宣布的截至2025年3月31日的恒 生指数系列季度检讨结果中,恒生指数成份股由83只增加至85只。 恒生指数成份股再"扩容" 8月22日,恒生指数有限公司(简称"恒生指数公司")宣布截至2025年6月30日的恒生指数系列季度检讨结 果,其中在港股市场最受关注的指数之一——恒生指数,成份股数目将进一步增加,由85只增加至88只, 加入中国电信、京东物流、泡泡玛特3只股票。 | 代號 | 公司 | 恒指分類指數 | | --- | --- | --- | | 728 | 中國電信股份有限公司 - H 股 | 恒生工商業分類指數 | | 2618 | 京東物流股份有限公司 | 恒生工商業分類指數 | | 9992 | 泡泡瑪特國際集團有限公司 | 恒生工商業分類指數 | 另一 ...
共享基经丨与AI一起读懂ETF(二十一):4个与创新药相关的指数将迎来调整,会有何不同?
Sou Hu Cai Jing· 2025-07-03 10:00
Group 1 - The Hang Seng Index Company announced adjustments to the calculation methods of several indices, including the Hang Seng Hong Kong Stock Connect Innovative Drug Index, Hang Seng Innovative Drug Index, Hang Seng Biotechnology Index, and Hang Seng Hong Kong-US Biotechnology Index [1] - The adjustments aim to enhance the focus on pure innovative drug companies by excluding companies primarily engaged in the CXO industry, which includes Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), and Contract Development and Manufacturing Organizations (CDMO) [2][4] - The changes will result in a more concentrated index composition, with the top five constituents of the Hang Seng Hong Kong Stock Connect Innovative Drug Index shifting to companies like Innovent Biologics, BeiGene, and others, while the previous weight of excluded companies was approximately 18.1% [3] Group 2 - The Hang Seng Biotechnology Index will see a reduction in the number of constituents from 50 to a fixed number of 30, along with new trading qualification requirements under the Stock Connect program [6] - The Hang Seng Hong Kong-US Biotechnology Index will also reduce its constituent count from 60 to a fixed number of 40, indicating a significant decrease in the number of stocks included [9] - The adjustments to the indices will take effect on June 30, 2025, with the changes in constituent stocks implemented on September 8, 2025 [9]
恒生生物科技指数及恒生港美生物科技指数的编算方法调整
news flash· 2025-06-26 08:05
Group 1 - The Hang Seng Biotechnology Index will undergo updates in its calculation methodology, including new requirements for the Stock Connect trading eligibility and modifications to the selection criteria [1] - The number of constituent stocks in the Hang Seng Biotechnology Index will be fixed at 30 [1] - The listing history requirement will be removed, and a rapid inclusion mechanism will be introduced [1] Group 2 - The Hang Seng Hong Kong-US Biotechnology Index will also see updates, with the number of constituent stocks fixed at 40 [1]